PMID- 23590680
OWN - NLM
STAT- MEDLINE
DCOM- 20140701
LR  - 20151119
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 5
IP  - 4
DP  - 2013 Dec
TI  - Liraglutide protects pancreatic beta cells during an early intervention in 
      Gato-Kakizaki rats.
PG  - 421-8
LID - 10.1111/1753-0407.12061 [doi]
AB  - BACKGROUND: Glucagon-like peptide-1 (GLP-1) analogues have emerged as insulin 
      secretagogues and are widely used in type 2 diabetic patients. GLP-1 analogues 
      also demonstrate a promotion of beta cell proliferation and reduction of 
      apoptosis in rodents. In the present study, we investigated the protection of 
      pancreatic beta cells by early use (at the age of 2 weeks) of GLP-1 analogue, 
      liraglutide in Gato-Kakizaki (GK) rats and explored the underlying mechanisms. 
      METHODS: The effects of liraglutide on glucose tolerance were evaluated by 
      intraperitoneal glucose tolerance test (IPGTT) and insulin release tests (IRT). 
      Ki67 and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
      (TUNEL) immunostaining, Western blots and real-time polymerase chain reaction 
      were applied to evaluate cell proliferation, apoptosis and related gene 
      expressions. RESULTS: Our results demonstrated that early use of liraglutide 
      improved glucose tolerance during liraglutide treatment in GK rats. Liraglutide 
      increased pancreatic insulin contents and markedly reduced beta cell apoptosis. 
      Liraglutide also downregulated pro-apoptotic gene expressions and reduced 
      intra-islet macrophage infiltration. CONCLUSIONS: This experiment reported for 
      the first time that early use of liraglutide could protect beta cell failure in 
      pre-diabetic GK rats through reduction of beta cell apoptosis and ameliorating 
      islet inflammation.
CI  - (c) 2013 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley 
      Publishing Asia Pty Ltd.
FAU - Luo, Xiu
AU  - Luo X
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of 
      Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Pan, Linlin
AU  - Pan L
FAU - Nie, Aifang
AU  - Nie A
FAU - Wang, Qidi
AU  - Wang Q
FAU - Gu, Yanyun
AU  - Gu Y
FAU - Li, Fengying
AU  - Li F
FAU - Zhang, Hongli
AU  - Zhang H
FAU - Li, Wenyi
AU  - Li W
FAU - Li, Xiaoying
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130604
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cytoprotection/*drug effects
MH  - Diabetes Mellitus, Experimental/*prevention & control
MH  - Drug Evaluation, Preclinical
MH  - Glucagon-Like Peptide 1/*analogs & derivatives/pharmacology
MH  - Glucose Intolerance/*drug therapy
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin-Secreting Cells/*drug effects/physiology
MH  - Liraglutide
MH  - Macrophages/drug effects/physiology
MH  - Male
MH  - Rats
MH  - Time Factors
OTO - NOTNLM
OT  - Goto-Kakizaki rats
OT  - Goto-Kakizaki大鼠，利拉鲁肽，胰腺beta细胞
OT  - liraglutide
OT  - pancreatic beta cells
EDAT- 2013/04/18 06:00
MHDA- 2014/07/02 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/25 00:00 [received]
PHST- 2013/03/11 00:00 [revised]
PHST- 2013/04/13 00:00 [accepted]
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2014/07/02 06:00 [medline]
AID - 10.1111/1753-0407.12061 [doi]
PST - ppublish
SO  - J Diabetes. 2013 Dec;5(4):421-8. doi: 10.1111/1753-0407.12061. Epub 2013 Jun 4.